Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease

被引：0
作者：
Panagiotis Alexopoulos
Lena-Sophie Gleixner
Lukas Werle
Felix Buhl
Nathalie Thierjung
Evangelia Giourou
Simone M. Kagerbauer
Philippos Gourzis
Hubert Kübler
Timo Grimmer
Igor Yakushev
Jan Martin
Alexander Kurz
Robert Perneczky
机构：
[1] Technical University of Munich,Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar
[2] University Hospital of Rion,Department of Psychiatry
[3] University of Patras,Department of Anaesthesiology, Klinikum Rechts der Isar
[4] Max Planck Institute of Psychiatry,Department of Urology, Klinikum Rechts der Isar
[5] Technical University of Munich,Department of Nuclear Medicine, Klinikum Rechts der Isar
[6] Technical University of Munich,Department of Psychiatry and Psychotherapy
[7] Technical University of Munich,Neuroepidemiology and Ageing Research Unit, Faculty of Medicine, School of Public Health
[8] Ludwig-Maximilians-Universität München,undefined
[9] The Imperial College of Science,undefined
[10] Technology and Medicine,undefined
[11] West London Mental Health NHS Trust,undefined
[12] German Center for Neurodegenerative Diseases (DZNE) Munich,undefined
来源：
European Archives of Psychiatry and Clinical Neuroscience | 2018年 / 268卷
关键词：
Soluble amyloid precursor protein β (sAPPβ); Biomarker-underpinned diagnoses; FDG-PET; Upstream biomarkers; Mild cognitive impairment; Dementia due to Alzheimer’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The established biomarkers of Alzheimer’s disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein β (sAPPβ), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPPβ in plasma as an AD biomarker candidate.
引用
收藏
页码：519 / 524
页数：5
相关论文
共 50 条
  • [1] Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer's disease
    Alexopoulos, Panagiotis
    Gleixner, Lena-Sophie
    Werle, Lukas
    Buhl, Felix
    Thierjung, Nathalie
    Giourou, Evangelia
    Kagerbauer, Simone M.
    Gourzis, Philippos
    Kuebler, Hubert
    Grimmer, Timo
    Yakushev, Igor
    Martin, Jan
    Kurz, Alexander
    Perneczky, Robert
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2018, 268 (05) : 519 - 524
  • [2] Decrease in Brain Soluble Amyloid Precursor Protein β (sAPPβ) in Alzheimer's Disease Cortex
    Wu, Guoxin
    Sankaranarayanan, Sethu
    Hsieh, Sidney H-K
    Simon, Adam J.
    Savage, Mary J.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (06) : 822 - 832
  • [3] Amyloid Precursor Protein Processing and Alzheimer's Disease
    O'Brien, Richard J.
    Wong, Philip C.
    ANNUAL REVIEW OF NEUROSCIENCE, VOL 34, 2011, 34 : 185 - 204
  • [4] Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers
    Perneczky, Robert
    Alexopoulos, Panagiotis
    Kurz, Alexander
    TRENDS IN MOLECULAR MEDICINE, 2014, 20 (01) : 8 - 15
  • [5] Plasma Levels of Amyloid-β Peptides and Tau Protein in Mexican Patients with Alzheimer's Disease
    Castillo-Mendieta, Tzayaka
    Arana-Lechuga, Yoaly
    Campos-Pena, Victoria
    Luisa Sosa, Ana
    Orozco-Suarez, Sandra
    Pinto-Almazan, Rodolfo
    Segura-Uribe, Julia
    Rodriguez-Sanchez de Tagle, Aldo Javier
    Ruiz-Sanchez, Elizabeth
    Guerra-Araiza, Christian
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 82 : S271 - S281
  • [6] Amyloid precursor protein in peripheral granulocytes as a potential biomarker for Alzheimer's disease
    Wang, Xiaonan
    Li, Xihai
    Yang, Jie
    Yu, Ming
    Wu, Jinmei
    BANGLADESH JOURNAL OF PHARMACOLOGY, 2016, 11 : S92 - S97
  • [7] CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease
    Perneczky, R.
    Tsolakidou, A.
    Arnold, A.
    Diehl-Schmid, J.
    Grimmer, T.
    Foerstl, H.
    Kurz, A.
    Alexopoulos, P.
    NEUROLOGY, 2011, 77 (01) : 35 - 38
  • [8] Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease
    Wu, Guoxin
    Sankaranarayanan, Sethu
    Wong, Jacky
    Tugusheva, Katherine
    Michener, Maria S.
    Shi, Xiaoping
    Cook, Jacquelynn J.
    Simon, Adam J.
    Savage, Mary J.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2012, 90 (12) : 2247 - 2258
  • [9] Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia
    Alexopoulos, Panagiotis
    Thierjung, Nathalie
    Economou, Polychronis
    Werle, Lukas
    Buhl, Felix
    Kagerbauer, Simone
    Papanastasiou, Anastasios D.
    Grimmer, Timo
    Gourzis, Philippos
    Berthele, Achim
    Hemmer, Bernhard
    Kuebler, Hubert
    Martin, Jan
    Politis, Antonios
    Perneczky, Robert
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 69 (01) : 83 - 90
  • [10] Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease
    Bekris, L. M.
    Galloway, N. M.
    Millard, S.
    Lockhart, D.
    Li, G.
    Galasko, D. R.
    Farlow, M. R.
    Clark, C. M.
    Quinn, J. F.
    Kaye, J. A.
    Schellenberg, G. D.
    Leverenz, J. B.
    Seubert, P.
    Tsuang, D. W.
    Peskind, E. R.
    Yu, C. E.
    NEUROBIOLOGY OF AGING, 2011, 32 (03) : 556.e13 - 556.e23
12345